Multiple mechanisms of heterologous beta-adrenoceptor regulation in rat uterus

Changes in lymphocyte glucocorticoid and beta-adrenergic receptors in veal calves treated with clenbuterol and steroid hormones for growth-promoting purposes*

In order to identify possible peripheral markers of illegal treatments with growth-promoting agents in veal calves, beta-adrenergic receptor (beta-AR) and glucocorticoid receptor (GR) concentrations were measured in lymphocytes of 12 male Friesian crossbred calves (six controls and six treated). The animals received a cocktail of anabolic and re-partitioning agents [17beta-oestradiol: 3 x 10 mg intramuscular (i.m.) doses at 17-day intervals; dexamethasone sodium phosphate: 4 mg/day for 6 days and 5 mg/day for six further days dissolved in milk; and clenbuterol: 20 microg/kg/day dissolved in milk for the last 40 days before slaughter]. Blood samples were collected by venipuncture at different time points and lymphocytes were isolated by density gradient centrifugation. Lymphocyte beta-AR and GR levels were measured by binding assays. Treatment with re-partitioning agents caused a significant down-regulation of lymphocyte beta-ARs 19 days after the beginning of clenbuterol administration and at day 55 (after dexamethasone withdrawal, just before slaughter). This phenomenon was partially reversed at day 50, after dexamethasone administration, at which time a significant decrease in GR concentrations also occurred. For both types of receptors, no significant changes in the dissociation constant values were observed at any time point. Lymphocytes express measurable concentrations of beta-ARs and GRs and the measurement of receptor levels highlights the fluctuation of receptor expression due to the dynamic interaction of the drugs used in combination. Lymphocyte receptor determination could therefore be included in a battery of biological assays to detect illegal treatments with anabolic agents in veal calves in the light of a multivariate approach.

Pregnancy-induced decrease in the relaxant effect of terbutaline in the late-pregnant rat myometrium: role of G-protein activation and progesterone

The effectiveness of beta2-agonists in preterm delivery is reduced by several factors. The aim of this study was to determine the influence of late pregnancy in the uterus-relaxing effect of terbutaline in the rat in vitro. Rat uterine tissues from late pregnancy (days 15, 18, 20 and 22) were used. In vitro electrical field-stimulation (EFS) was used to evoke contractions. The radioligand-binding technique, reverse transcription-polymerase chain reaction and radioimmunoassay technique were used to determine the beta-adrenergic receptor density and mRNA level and the plasma sex hormone level, respectively. The activated G-protein level of the beta-adrenergic receptors was investigated by a radiolabelled GTP binding assay.EFS-induced contractions were inhibited by terbutaline. This effect decreased towards term with respect to both the EC50 and maximal inhibition values. A drop in plasma progesterone level was also detected. Binding studies revealed an increase in beta-adrenergic receptor number on the last day of pregnancy, which correlated with the change in receptor mRNA level. The G-protein-activating effect of terbutaline decreased continuously between days 15 and 20. Surprisingly, terbutaline decreased the G-protein activation to below the basal level on day 22. However, progesterone pretreatment set back the uterine action of terbutaline, increased the density of the beta2-adrenergic receptors and their mRNA level and increased the G-protein-activating property of terbutaline. These data provide evidence of a pregnancy-induced decrease in activated G-protein level after beta2-agonist stimulation. The decrease in plasma progesterone level has a crucial role in this process. The effects of beta2-adrenergic receptor agonists in tocolytic therapy may possibly be potentiated with progesterone.

Characterization and localization of beta2-adrenergic receptors in the bovine oviduct: indication for progesterone-mediated expression

Beta2-adrenergic receptors were detected in bovine oviductal epithelium by use of receptor binding studies and expression analysis. Complementary DNA cloning gave use to the first full-length bovine beta2-adrenoceptor messenger RNA sequence (2030 bases). Receptor bioactivity in oviduct epithelial cells was characterized by specific ligand interaction and consequent cAMP generation. Expression studies demonstrated an estrous cycle-dependent regulation, with higher transcript levels and significantly increased binding capacity during the luteal phase. After progesterone supplementation, oviduct epithelial cells showed elevated receptor expression in culture, supporting the hypothesis that progesterone up-regulates the beta2-adrenergic receptor within these cells. It seems likely that catecholamines from the circulation or from innervation might be able to influence reproductive success by regulating oviductal secretion.

Expression of beta-adrenergic receptors in the rat uterus: effects of puberty and oestrogen treatment during prepubertal development

The expression of beta-adrenoceptors in the rat uterus has been analysed during the peripubertal transition and following acute and chronic oestradiol treatment during prepubertal development. The distribution and density of beta-adrenoceptors was assessed autoradiographically on cryostat tissue sections using [3H]-dihydroalprenolol ([3H]-DHA). Binding sites were localised in all ages and experimental situations examined and showed the following intensity of labelling: endometrial epithelium > longitudinal muscle layer > circular myometrial layer > endometrial stroma. Competition experiments with the selective antagonists ICI 118,551 and atenolol, showed that most of the beta-adrenoceptors in the uterus belong to the beta(2) receptor subclass. In prepubertal animals, the density of [3H]-DHA binding sites was extremely low. Following puberty the density of binding sites showed a generalised increase. Acute administration of oestradiol at the end of the prepubertal period provoked an increase in the density of [3H]-DHA binding sites in all uterine regions, but the levels of labelling were lower than in peripubertal animals at proestrus and oestrus. Following chronic oestrogen treatment during postnatal development, oestradiol increased further the density of [3H]-DHA binding sites. Results are discussed considering both the endocrine and neural changes accompanying puberty and oestradiol treatment.